ArticleDiabetic medicine : a journal of the British Diabetic Association2022

INnoVative trial design for testing the Efficacy, Safety and Tolerability of 6-month treatment with incretin-based therapy to prevent type 1 DIAbetes in autoantibody positive participants: A protocol for three parallel double-blind, randomised controlled trials (INVESTDIA).

Jukka Kero et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.